Nature Communications (Sep 2020)
Bone morphogenetic protein 7 promotes resistance to immunotherapy
- Maria Angelica Cortez,
- Fatemeh Masrorpour,
- Cristina Ivan,
- Jie Zhang,
- Ahmed I. Younes,
- Yue Lu,
- Marcos R Estecio,
- Hampartsoum B. Barsoumian,
- Hari Menon,
- Mauricio da Silva Caetano,
- Rishab Ramapriyan,
- Jonathan E. Schoenhals,
- Xiaohong Wang,
- Ferdinandos Skoulidis,
- Mark D. Wasley,
- George Calin,
- Patrick Hwu,
- James W. Welsh
Affiliations
- Maria Angelica Cortez
- Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Fatemeh Masrorpour
- Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Cristina Ivan
- Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Jie Zhang
- Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Ahmed I. Younes
- Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Yue Lu
- Epigenetic and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center
- Marcos R Estecio
- Epigenetic and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center
- Hampartsoum B. Barsoumian
- Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Hari Menon
- Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Mauricio da Silva Caetano
- Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Rishab Ramapriyan
- Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Jonathan E. Schoenhals
- Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Xiaohong Wang
- Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Ferdinandos Skoulidis
- Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Mark D. Wasley
- Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- George Calin
- Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Patrick Hwu
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center
- James W. Welsh
- Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-020-18617-z
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
The mechanisms underlying resistance to immunotherapy are still poorly understood. Here, the authors show that BMP7, a molecule part of the TGF-beta superfamily, suppresses proinflammatory antitumor responses and may represent a target for overcoming resistance to PD1 inhibitors.
